Sai Life Sciences , a prominent player in the pharmaceutical industry, has announced the allotment of 2,49,969 fully paid-up equity shares under its employee stock option plans. This move, approved by the company's Board of Directors through a circular resolution dated November 4, 2025, aims to attract, retain, and reward employees.

Details of the Allotment

The allotment includes shares issued under two distinct employee stock option plans:

Impact on Share Capital

Following this allotment, Sai Life Sciences' total issued share capital has increased to 210,171,761 shares. The newly allotted shares have been issued in dematerialized form with the ISIN number INE570L01029.

Employee Stock Option Plans

The company's employee stock option plans, ESOP 2008 and MESOP 2018, are designed with a maximum vesting period of 5 years. These plans offer flexibility with multiple vesting options, allowing employees to exercise their options as long as they remain in the company's service.

Financial Implications

The total money realized by the company through this exercise of options amounts to INR 1,74,52,745.70. This infusion of capital could potentially contribute to the company's growth initiatives and operational needs.

Regulatory Compliance

Sai Life Sciences has ensured compliance with the Securities and Exchange Board of India (SEBI) regulations, including the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

This allotment of shares under the employee stock option plans underscores Sai Life Sciences' commitment to aligning employee interests with the company's long-term growth objectives.

Sai Life Sciences , a rapidly growing Contract Research, Development, and Manufacturing Organization (CRDMO), has announced plans to significantly expand its research and development capabilities. The company has broken ground on a new CMC Process R&D Center at its integrated R&D campus in Hyderabad, marking a major step in its growth strategy.

Expansion Details

The new facility, expected to be operational by September 2026, is designed to double the company's Process R&D capacity. Here are the key features of the upcoming center:

Strategic Importance

This expansion is part of Sai Life Sciences' planned capital expenditure, driven by increasing demand for late-stage development programs and scalable CMC capacity. The investment reflects the company's strong business momentum and expanding engagement with global pharmaceutical and biotech partners.

Krishna Kanumuri, CEO & Managing Director of Sai Life Sciences, emphasized the strategic importance of this expansion, stating, "As our partners seek greater speed, flexibility, and scientific depth, we are scaling our capabilities to move programs faster and more efficiently through the development continuum."

New Capabilities

The new center introduces several new capabilities to Sai Life Sciences' portfolio:

• Peptide development
• Oligo intermediates & linkers development
• Formulation development
• Early-phase clinical supplies

These additions are expected to enhance the company's ability to support both Full-Time Equivalent (FTE) and Dedicated Project Capacity (DPC) engagement models, enabling more flexible collaboration with global innovators from early development to late-stage CMC programs.

Industry Impact

This expansion positions Sai Life Sciences to better meet the growing demand for end-to-end, partnership-driven solutions in the pharmaceutical and biotech industries. By combining scientific excellence with execution agility, the company aims to accelerate the discovery, development, and commercialization of small molecules and emerging modalities.

As the pharmaceutical landscape continues to evolve, with timelines becoming increasingly compressed, Sai Life Sciences' investment in this new CMC Process R&D Center demonstrates its commitment to staying at the forefront of the industry and delivering innovative solutions to its partners worldwide.